Seroquel (Quetiapine) Dosing Recommendations
For elderly patients, start Seroquel at 50 mg/day with slower titration in 50 mg increments, while adults should begin at 25 mg twice daily and titrate more rapidly based on indication. 1
Adult Dosing (Non-Elderly)
Schizophrenia
- Initial titration: Start 25 mg twice daily on Day 1
- Increase by 25-50 mg divided 2-3 times daily on Days 2-3
- Target 300-400 mg/day by Day 4
- Recommended dose range: 150-750 mg/day
- Maximum: 750 mg/day
- Further adjustments in 25-50 mg increments, minimum 2-day intervals 1
Bipolar Mania (Monotherapy or Adjunct)
- Day 1: 100 mg total (divided twice daily)
- Day 2: 200 mg total
- Day 3: 300 mg total
- Day 4: 400 mg total
- Can increase up to 800 mg/day by Day 6 in 200 mg increments
- Recommended dose: 400-800 mg/day
- Maximum: 800 mg/day 1
Bipolar Depression
- Administer once daily at bedtime
- Day 1: 50 mg
- Day 2: 100 mg
- Day 3: 200 mg
- Day 4: 300 mg
- Target and maximum dose: 300 mg/day 1
Elderly Patient Dosing (≥65 Years)
Critical distinction: Elderly patients require substantially different dosing due to altered pharmacokinetics and increased sensitivity to adverse effects, particularly orthostatic hypotension and falls 2, 3.
- Starting dose: 50 mg/day (NOT 25 mg twice daily as in adults)
- Titration: Increase in 50 mg/day increments
- Rate: Slower than adults - allow adequate time between increases to assess tolerability
- Monitor closely for: Orthostatic hypotension, sedation, falls risk 1
Specific Elderly Context: Alzheimer's Disease/Dementia-Related Agitation
When used for behavioral symptoms in dementia (noting this is off-label):
- Starting dose: 12.5 mg twice daily
- Maximum: 200 mg twice daily
- Key warning: More sedating than other atypicals; monitor for transient orthostasis 2
Elderly Context: Delirium Management
- Starting dose: 25 mg (immediate release) orally
- Can reduce to 12.5 mg in frail/older patients
- Maximum: 200 mg twice daily
- Monitor for orthostatic hypotension and dizziness 4
Special Population Adjustments
Hepatic Impairment
- Starting dose: 25 mg/day
- Titration: Increase daily in 25-50 mg increments to effective dose
- Base increases on clinical response and tolerability 1
Drug Interactions
With CYP3A4 Inhibitors (ketoconazole, itraconazole, ritonavir):
- Reduce Seroquel dose to one-sixth of original dose
- When inhibitor discontinued, increase back 6-fold 1
With CYP3A4 Inducers (phenytoin, carbamazepine, rifampin):
- Increase Seroquel up to 5-fold of original dose for chronic treatment (>7-14 days)
- When inducer discontinued, reduce to original level within 7-14 days 1
Critical Safety Considerations
Elderly-Specific Risks
The evidence strongly indicates elderly patients face substantially higher risks:
- Orthostatic hypotension is the primary concern - occurs frequently with quetiapine 2
- Falls risk is significantly elevated compared to alternatives like trazodone 5
- Mortality risk may be increased, particularly compared to trazodone (HR 3.1) 5
- Dementia risk appears elevated in elderly using low-dose quetiapine for insomnia (HR 7.1-8.1) 5
Common Pitfalls to Avoid
Do not use adult titration schedules in elderly patients - this is the most common error. The 25 mg twice daily starting dose is inappropriate for elderly; use 50 mg once daily instead 1
Do not ignore orthostatic vital signs - check blood pressure sitting and standing, especially during titration in elderly patients 2, 3
Beware paradoxical agitation - while rare, can occur in elderly patients; if observed, reduce dose or switch agents 2
Monitor for excessive sedation - quetiapine is described as "more sedating" than other atypicals; this is particularly problematic in elderly 2
Re-initiation After Discontinuation
- Off >1 week: Follow initial dosing schedule
- Off <1 week: May re-initiate maintenance dose without gradual escalation 1
Evidence Quality Note
The FDA label 1 provides the definitive dosing framework. The Alzheimer's guidelines 2 offer specific elderly dosing that differs substantially from general adult recommendations. Recent safety data 5 raises significant concerns about quetiapine use in elderly, particularly for off-label indications like insomnia, showing increased mortality and dementia risk compared to alternatives.